全文获取类型
收费全文 | 4698167篇 |
免费 | 358475篇 |
国内免费 | 14624篇 |
专业分类
耳鼻咽喉 | 66071篇 |
儿科学 | 146590篇 |
妇产科学 | 123556篇 |
基础医学 | 710951篇 |
口腔科学 | 130369篇 |
临床医学 | 425741篇 |
内科学 | 851581篇 |
皮肤病学 | 114228篇 |
神经病学 | 385395篇 |
特种医学 | 182386篇 |
外国民族医学 | 571篇 |
外科学 | 723045篇 |
综合类 | 129864篇 |
现状与发展 | 23篇 |
一般理论 | 2680篇 |
预防医学 | 385613篇 |
眼科学 | 111378篇 |
药学 | 333550篇 |
28篇 | |
中国医学 | 12496篇 |
肿瘤学 | 235150篇 |
出版年
2021年 | 56067篇 |
2019年 | 58697篇 |
2018年 | 74700篇 |
2017年 | 57137篇 |
2016年 | 63327篇 |
2015年 | 76056篇 |
2014年 | 110508篇 |
2013年 | 175734篇 |
2012年 | 131223篇 |
2011年 | 138292篇 |
2010年 | 128375篇 |
2009年 | 128731篇 |
2008年 | 125082篇 |
2007年 | 133880篇 |
2006年 | 142195篇 |
2005年 | 137128篇 |
2004年 | 137200篇 |
2003年 | 127376篇 |
2002年 | 116695篇 |
2001年 | 180808篇 |
2000年 | 177049篇 |
1999年 | 160801篇 |
1998年 | 73322篇 |
1997年 | 68454篇 |
1996年 | 66634篇 |
1995年 | 61888篇 |
1994年 | 55845篇 |
1993年 | 51860篇 |
1992年 | 117193篇 |
1991年 | 113045篇 |
1990年 | 109054篇 |
1989年 | 106312篇 |
1988年 | 97801篇 |
1987年 | 96008篇 |
1986年 | 90169篇 |
1985年 | 88847篇 |
1984年 | 72442篇 |
1983年 | 64432篇 |
1982年 | 49457篇 |
1981年 | 46010篇 |
1980年 | 43131篇 |
1979年 | 63097篇 |
1978年 | 50172篇 |
1977年 | 44274篇 |
1976年 | 40907篇 |
1975年 | 41714篇 |
1974年 | 46374篇 |
1973年 | 44209篇 |
1972年 | 41539篇 |
1971年 | 38868篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Bladder mucosa in urethral reconstructions 总被引:6,自引:0,他引:6
992.
993.
994.
995.
996.
997.
Howard Morgan M.D. 《Surgical neurology》1990,33(6):413-416
The Russian writer Dostoevsky (1821–1881) suffered from a rare form of temporal lobe epilepsy termed “ec-static epilepsy.” Dostoevsky used his epileptic experiences to create Prince Myshkin, the protagonist of The Idiot. The recent case of a patient who experienced ecstatic epilepsy as a result of a temporal lobe brain tumor is presented and compared with that of Prince Myshkin. Reading Dostoevsky can give the contemporary physician an insight into the inner life of an epileptic patient — an example of how art can directly benefit medical practice. 相似文献
998.
999.
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients 总被引:1,自引:0,他引:1
R H Kerman C T Van Buren R M Lewis V DeVera V Baghdahsarian K Gerolami B D Kahan 《Transplantation》1990,49(1):52-56
We compared our standard NIH (extended incubation) crossmatch (XM) with antihuman globulin (AHG) and flow cytometry XMs and correlated the results with rejection episodes and graft survivals. For 89 CsA-Pred, primary renal allograft recipients, AHG and/or FCXM results did not improve on the NIH-XM-negative (NEG) graft survival results, whether testing pretransplant or historical (Hx) sera. Similarly, there was no association of a positive (POS) AHG or FCXM with increased rejection episodes in these primary recipients. However, for retransplant (Re-Tx) recipients a neg AHG or FCXM did discriminate fewer rejections and an improved graft survival compared with the NIH-XM-neg. results. The overall one-year graft survival for the 47 Re-Tx recipients studied herein was 66% (based on a neg pre-Tx NIH-XM). Pre-Tx AHG-NEG, Re-Tx recipients displayed an improved graft survival compared with NIH-XM NEG recipients (77% vs. 66%, P less than 0.05) and with AHG-POS recipients (77% vs. 47%, P less than 0.05). Similarly, pre-Tx, FCXM-NEG, Re-Tx recipients displayed improved graft survivals compared with NIH-XM-NEG recipients (83% vs. 66%, P less than 0.05) and FCXM-POS recipients (83% vs. 48%, P less than 0.05). Re-Tx recipients displaying a POS AHG and/or FCXM experienced a significantly greater number of rejections than NEG-XM recipients (P less than 0.05, respectively). The AHG and FCXM results correlated with rejections and graft survivals whether testing pre-Tx or Hx high-PRA sera. Re-Tx recipients who were AHG-XM-NEG but FCXM-POS, experienced more rejection episodes than recipients who displayed a negative XM reactivity for both AHG and FCXM (P less than 0.02), but with no resulting differences in graft survival. HLA matching, pre-Tx blood transfusions and PRA did not impact on these crossmatch and graft survival results. Use of AHG and/or FCXMs for Re-Tx, but not primary, recipients should help to improve graft survival for these high-risk recipients. 相似文献
1000.
P A Lear 《Transplantation proceedings》1990,22(6):2441-2442